Nature Communications (Dec 2016)
MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated
- Michal Smida,
- Ferran Fece de la Cruz,
- Claudia Kerzendorfer,
- Iris Z. Uras,
- Barbara Mair,
- Abdelghani Mazouzi,
- Tereza Suchankova,
- Tomasz Konopka,
- Amanda M. Katz,
- Keren Paz,
- Katalin Nagy-Bojarszky,
- Markus K. Muellner,
- Zsuzsanna Bago-Horvath,
- Eric B. Haura,
- Joanna I. Loizou,
- Sebastian M. B. Nijman
Affiliations
- Michal Smida
- Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM)
- Ferran Fece de la Cruz
- Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM)
- Claudia Kerzendorfer
- Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM)
- Iris Z. Uras
- Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM)
- Barbara Mair
- Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM)
- Abdelghani Mazouzi
- Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM)
- Tereza Suchankova
- Academy of Sciences of the Czech Republic, Institute of Biophysics
- Tomasz Konopka
- Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM)
- Amanda M. Katz
- Champions Oncology
- Keren Paz
- Champions Oncology
- Katalin Nagy-Bojarszky
- Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM)
- Markus K. Muellner
- Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM)
- Zsuzsanna Bago-Horvath
- Institute of Pharmacology and Toxicology, University of Veterinary Medicine
- Eric B. Haura
- Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute
- Joanna I. Loizou
- Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM)
- Sebastian M. B. Nijman
- Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM)
- DOI
- https://doi.org/10.1038/ncomms13701
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 13
Abstract
ATM is a tumor suppressor often mutated in lung adenocarcinoma. In this study, the authors starting from a synthetic lethal screen, demonstrate that tumor cells with mutations in ATM exhibit increased sensitivity to MEK1/2 inhibition through the modulation of the AKT/mTOR pathway.
